Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5930712 | 0.84 | TGFBR1 (0.48) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138393 | 0.82 | TGFBR1 (0.47) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5137965 | 0.82 | TGFBR1 (0.47) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5186774 | 0.80 | TGFBR1 (0.54) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138791 | 0.80 | TGFBR1 (0.46) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL27628468 | 0.80 | TGFBR1 (0.44) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL15849494 | 0.79 | TGFBR1 (0.62) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5139748 | 0.79 | TGFBR1 (0.46) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL3242826 | 0.78 | TGFBR1 (0.55) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5200243 | 0.76 | TGFBR1 (0.49) | TGFBR1MAPK14RIPK2ACVR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025451-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2006-02-02 | — | — | US | claimed |
| EP-2165708-A2 | NEW PYRAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20100056571-A1 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7638537-B2 | Pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1542684-B1 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PROD INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20070117850-A1 | substituted or unsubstituted 2-pyridyl moiety and a pyrozole ring substituted at 4 position with pyridine ring; inhibits the TGF-beta signaling pathway; anticancer, antifibrotic, antitumor, and antiproliferative agents | PFIZER INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-7151110-B2 | Pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060025451-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2006-02-02 | — | — | US | disclosed |
| US-6958354-B2 | Pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1542684-A2 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116474-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| WO-2004026306-A2 | PYRAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025451-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885MAPK14 189/4885RIPK2 181/4885 |
| US-20100056571-A1 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885MAPK14 170/4885RIPK2 167/4885 |
| US-20070117850-A1 | substituted or unsubstituted 2-pyridyl moiety and a pyrozole ring substituted at 4 position with pyridine ring; inhibits the TGF-beta signaling pathway; anticancer, antifibrotic, antitumor, and antiproliferative agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885MAPK14 159/4885RIPK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.